{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:49:43Z","timestamp":1794368983228,"version":"4.9.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,7,13]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>The complexity and dynamics of mutations significantly impact on response, progression, and prognosis in midostaurin-treated advSM patients.<\/jats:p>","DOI":"10.1182\/blood-2017-01-764423","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T00:55:23Z","timestamp":1492649723000},"page":"137-145","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":103,"title":["Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers"],"prefix":"10.1182","volume":"130","author":[{"given":"Mohamad","family":"Jawhar","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Mannheim University Medical Center, Mannheim, Germany;"},{"name":"Mannheim Medical Faculty, Heidelberg University, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Schwaab","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Mannheim University Medical Center, Mannheim, Germany;"},{"name":"Mannheim Medical Faculty, Heidelberg University, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Naumann","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Mannheim University Medical Center, Mannheim, Germany;"},{"name":"Mannheim Medical Faculty, Heidelberg University, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Horny","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Ludwig Maximilian University, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Sotlar","sequence":"additional","affiliation":[{"name":"University Institute of Pathology, Salzburg University Hospital, Paracelsus Medical University, Salzburg, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[{"name":"Munich Leukemia Laboratory, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Metzgeroth","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Mannheim University Medical Center, Mannheim, Germany;"},{"name":"Mannheim Medical Faculty, Heidelberg University, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Fabarius","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Mannheim University Medical Center, Mannheim, Germany;"},{"name":"Mannheim Medical Faculty, Heidelberg University, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[{"name":"Division of Hematology and Ludwig Boltzmann Cluster Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Karsten","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Mannheim University Medical Center, Mannheim, Germany;"},{"name":"Mannheim Medical Faculty, Heidelberg University, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[{"name":"Wessex Regional Genetics Laboratory, Salisbury, United Kingdom; and"},{"name":"Faculty of Medicine, University of Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manja","family":"Meggendorfer","sequence":"additional","affiliation":[{"name":"Munich Leukemia Laboratory, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Mannheim University Medical Center, Mannheim, Germany;"},{"name":"Mannheim Medical Faculty, Heidelberg University, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111909015257300_B1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ajh.23931","article-title":"Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management","volume":"90","author":"Pardanani","year":"2015","journal-title":"Am J Hematol"},{"issue":"6","key":"2019111909015257300_B2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"issue":"7","key":"2019111909015257300_B3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"issue":"2","key":"2019111909015257300_B4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111909015257300_B5","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2019111909015257300_B6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"2019111909015257300_B7","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.13865","article-title":"ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis","volume":"175","author":"Pardanani","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111909015257300_B8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/leu.2015.4","article-title":"Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event","volume":"29","author":"Jawhar","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"2019111909015257300_B9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","article-title":"The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis","volume":"93","author":"Erben","year":"2014","journal-title":"Ann Hematol"},{"issue":"1","key":"2019111909015257300_B10","doi-asserted-by":"crossref","first-page":"e85362","DOI":"10.1371\/journal.pone.0085362","article-title":"ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases","volume":"9","author":"Damaj","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"2019111909015257300_B11","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1038\/leu.2016.190","article-title":"Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2\/ASXL1\/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"issue":"26","key":"2019111909015257300_B12","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"2019111909015257300_B13","first-page":"54","article-title":"Mastocytosis (mast cell disease)","volume-title":"World Health Organization (WHO) Classification of Tumours. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues","author":"Horny","year":"2008"},{"issue":"20","key":"2019111909015257300_B14","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2019111909015257300_B15","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk Res"},{"issue":"3","key":"2019111909015257300_B16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjh.14269","article-title":"Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera","volume":"175","author":"Delic","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111909015257300_B17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jmoldx.2013.03.003","article-title":"Robustness of amplicon deep sequencing underlines its utility in clinical applications","volume":"15","author":"Grossmann","year":"2013","journal-title":"J Mol Diagn"},{"issue":"1","key":"2019111909015257300_B18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/leu.2013.239","article-title":"Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease","volume":"28","author":"Kohlmann","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"2019111909015257300_B19","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1182\/blood-2015-11-679167","article-title":"Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure","volume":"128","author":"Mossner","year":"2016","journal-title":"Blood"},{"key":"2019111909015257300_B20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2105-15-35","article-title":"Inferring clonal evolution of tumors from single nucleotide somatic mutations","volume":"15","author":"Jiao","year":"2014","journal-title":"BMC Bioinformatics"},{"issue":"26","key":"2019111909015257300_B21","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1056\/NEJMc1515403","article-title":"Midostaurin in advanced systemic mastocytosis","volume":"374","author":"Chandesris","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111909015257300_B22","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"issue":"29","key":"2019111909015257300_B23","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111909015257300_B24","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.bbmt.2016.04.018","article-title":"Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis","volume":"22","author":"Ustun","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111909015257300_B25","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"2019111909015257300_B26","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2019111909015257300_B27","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2019111909015257300_B28","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/leu.2015.129","article-title":"Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression","volume":"30","author":"Pellagatti","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"2019111909015257300_B29","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111909015257300_B30","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1200\/JCO.2013.48.9120","article-title":"Importance of genetics in the clinical management of chronic myelomonocytic leukemia","volume":"31","author":"Padron","year":"2013","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111909015257300_B31","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2019111909015257300_B32","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019111909015257300_B33","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2014.115840","article-title":"Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I","volume":"100","author":"Verstovsek","year":"2015","journal-title":"Haematologica"},{"issue":"2","key":"2019111909015257300_B34","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","article-title":"PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects","volume":"107","author":"Gleixner","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2019111909015257300_B35","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood-2010-06-289959","article-title":"KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib","volume":"118","author":"Gleixner","year":"2011","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/2\/137\/1403894\/blood764423.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/2\/137\/1403894\/blood764423.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T14:03:56Z","timestamp":1574172236000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/2\/137\/36698\/Response-and-progression-on-midostaurin-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,13]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,7,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-01-764423","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,13]]}}}